Dabigatran etexilate for preventing stroke and systemic embolism in atrial fibrillation

    Research output: Contribution to journalReview articlepeer-review

    Abstract

    Compared with warfarin in patients with nonvalvular atrial fibrillation, dabigatran at a dose of 150 mg twice daily is more effective for the prevention of stroke and systemic embolism with a similar risk of major bleeding, and at a dose of 110 mg twice daily has similar effectiveness with less major bleeding. The TGA recommends use of the higher dose except in patients aged over 75 years or with a high bleeding risk or with moderate renal impairment, where they suggest the lower dose should be used.

    Original languageEnglish
    Pages (from-to)69-75
    Number of pages7
    JournalMedicine Today
    Volume14
    Issue number3
    Publication statusPublished - Mar 2013

    Fingerprint Dive into the research topics of 'Dabigatran etexilate for preventing stroke and systemic embolism in atrial fibrillation'. Together they form a unique fingerprint.

    Cite this